Published in:
01-02-2007 | Editorial
The strange case of TGN1412
Authors:
L. Farzaneh, N. Kasahara, F. Farzaneh
Published in:
Cancer Immunology, Immunotherapy
|
Issue 2/2007
Login to get access
Excerpt
A current focus of cancer research is the development of immunostimulatory therapeutic antibodies, based on the notion that increasing the number or activity of cytotoxic T lymphocytes, and in particular those directed against tumour-associated antigens, may achieve effective immune mediated tumour rejection. Unlike other techniques, such as the use of antibodies specific to tumour cells themselves, this approach does not rely on antigen-specificity, and accordingly is subject to risks of autoimmunity as a consequence of non-specific activation of T cells [
1]. …